Valeritas presents data from preclinical h-Patch Apomorphine study
Valeritas Holdings announced data from its preclinical pharmacokinetic study of apomorphine subcutaneous infusion was presented today at Global Experts Meeting on Frontiers in Alzheimer's Disease & Dementia in Rome, Italy. In the poster presentation titled "Preclinical Pilot Study Result of 24-Hour Apomorphine Subcutaneous Infusion Delivered via the h-Patch Wearable Device," the data demonstrated rapid absorption and distribution of 400ul of a 25mg/ml APO solution with the h-Patch technology. APO was detected in plasma within two hours of the start of infusion, and still detectable 24 hours after completion of h-Patch infusion, or 48 hours in total. Close to a dozen clinical studies have shown subcutaneous Apo infusions are successful in aborting "off" periods, reducing dyskinesias, and improving PD motor scores with the added benefit of a substantial levodopa-sparing effect. However, bulky infusion pumps requiring delivery of relatively large volumes of therapeutics remain a barrier to the development of therapeutic products that are patient and caregiver friendly.